30fdca7b-ecb1-4096-b2d2-41831f283ae1
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 80
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.520
- INTERFERON_GAMMA_RESPONSE+0.420
- ALLOGRAFT_REJECTION+0.400
- IL6_JAK_STAT3_SIGNALING+0.330
- INFLAMMATORY_RESPONSE+0.330
- TNFA_SIGNALING_VIA_NFKB+0.230
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.210
- KRAS_SIGNALING_UP+0.210
- COMPLEMENT+0.180
- IL2_STAT5_SIGNALING+0.180
Top 10 suppressed
- G2M_CHECKPOINT-0.490
- E2F_TARGETS-0.420
- PANCREAS_BETA_CELLS-0.350
- FATTY_ACID_METABOLISM-0.340
- MITOTIC_SPINDLE-0.320
- CHOLESTEROL_HOMEOSTASIS-0.270
- ADIPOGENESIS-0.260
- MYC_TARGETS_V1-0.260
- ESTROGEN_RESPONSE_LATE-0.240
- OXIDATIVE_PHOSPHORYLATION-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-03976 | — | cohortMD2 | 0.855 |
| 2 | 46a6f49d-2ab8-41fb-ba8c-951a160e5d08 | — | — | 0.840 |
| 3 | TCGA-97-A4LX-01A-11R-A24X-07 | — | cohortA1 | 0.836 |
| 4 | SRR12202486 | — | — | 0.831 |
| 5 | SRR8942969 | — | — | 0.822 |
| 6 | TCGA-MP-A4T4-01A-11R-A262-07 | — | cohortA1 | 0.815 |
| 7 | 94b2af92-0cfc-40b2-977d-6bd0fa4440d9 | — | — | 0.812 |
| 8 | TCGA-55-8208-01A-11R-2241-07 | — | cohortMD2 | 0.809 |
| 9 | MBCProject_0375_T1_A_RNA | — | D | 0.803 |
| 10 | C3N-02920 | — | cohortA1 | 0.802 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.520 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.330 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.330 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.230 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.210 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.210 | Inavolisib | — uncovered |
| COMPLEMENT | 0.180 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| COAGULATION | 0.150 | Binimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.130 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.130 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.070 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.030 | Inavolisib | — uncovered |
| MYOGENESIS | 0.030 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.020 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.020 | Idelalisib | — uncovered |